Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3K citations

Neurodegenerative Diseases, Alzheimer's Disease, Medicine +7

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Leslie M. Shaw, Hugo Vanderstichele, Małgorzata Knapik-Czajka et al. · Annals of Neurology · 2009 · 2.1K citations · Full text

Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease

Lih-Fen Lue, Yu‐Min Kuo, Alex E. Roher et al. · American Journal Of Pathology · 1999 · 1.5K citations

Synaptic Plasticity, Neurodegenerative Diseases, Alzheimer's Disease +12

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

Amir Qaseem, Vincenza Snow, J. Thomas Cross et al. · Annals of Internal Medicine · 2008 · 346 citations

Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis

Francine Gervais, Julie Paquette, Céline Morissette et al. · Neurobiology of Aging · 2006 · 301 citations

Neurodegenerative Diseases, Medicine, Peptide Engineering +8